天眼查App显示，近日，宜宾科豪生物科技有限公司成立，法定代表人为丁佳豪，注册资本50万人民 币，经营范围为一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；牲畜销 售；再生资源回收（除生产性废旧金属）。（除依法须经批准的项目外，凭营业执照依法自主开展经营 活动）许可项目：餐厨垃圾处理；城市生活垃圾经营性服务；家禽饲养；活禽销售；牲畜饲养。（依法 须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件 为准）（涉及国家规定实施准入特别管理措施的除外）。 ...

中新网深圳12月10日电 记者10日从总部位于深圳的华大集团获悉，由国际标准化组织生物技术委员会 (ISO/TC276)归口，总部位于深圳的华大集团联合多家机构共同研制的国际标准《ISO20309:2025 Biotechnology— Biobanking— Requirements for deep-sea biological material》(暂译名：生物技术—生物样 本库—深海生物样本保藏要求)，于9日正式发布。 该标准的发布，标志着源自中国的深海生物样本保藏技术方案，已成功转化为全球通行的国际标准，实 现了中国在该领域从"中国规范"到"全球标杆"的跨越。 国际标准化组织(ISO)官网截图。华大供图 （文章来源：中国新闻网） 据悉，该项目团队研制的中国国家标准GB/T46753-2025《深海生物样本采集、处理和保藏要求》经国 家标准化委员会批准于12月2日正式发布。 该项目自2022年12月向国际标准化组织(ISO)申请立项以来，华大集团与中国科学院深海科学与工程研 究所、上海交通大学、中国水产科学研究院黄海水产研究所、中国食品发酵工业研究院有限公司等合作 单位紧密配合，针对各种深海生物样本处理 ...

证券之星消息，根据天眼查APP于11月26日公布的信息整理，上海唯可生物科技有限公司A轮融资，融 资额近亿人民币，参与投资的机构包括深创投，锡创投。 数据来源：天眼查APP 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 公布日 | 投资方 | 交易金额 | 融资轮次 | | --- | --- | --- | --- | | 2025-11-26 | 深创投 | 近亿人民币 | A轮 | | | 锡创投 | | | | 2024-09-12 | 邦明资本 深高新投 | 数千万人民币 | Pre-A轮 | | | 祥榕投资 | | | | 2022-12-19 | 华大共赢 | 数千万人民币 | 天使轮 | | 2022-06-07 | 欧源咨本 | 未披露 | 种子轮 | 上海唯可生物科技有限公司成立于2021年3月8日，是符合国内监管需求开展整合病毒插入位点分析 （ISA）的创新性企业，在基因治疗安全评价领域处于行业领先地位。唯可生物主要致力于基因治疗插 入突变风险评估, 高精度crispr/cas 9定量脱靶分析,载体拷贝 ...

Core Viewpoint - The company has reported significant growth in its third-quarter performance, with a focus on enhancing its core business and expanding into international markets, while also undergoing governance changes by eliminating the supervisory board [2][3][26]. Financial Performance - The company's third-quarter revenue increased by 17.71% compared to the previous quarter [2]. - New orders increased by 29.37% year-on-year, with a notable 30.71% growth in new drug clinical trial applications (IND) and new drug marketing applications (NDA) [2]. - The total order amount on hand grew by 19.43% compared to the end of 2024, providing a solid foundation for future operations [2]. Market Expansion - The company has established diverse marketing channels to enhance its international market presence, resulting in a significant increase in new orders from overseas markets [3]. - The focus on innovative drug development includes high-potential areas such as CAR-T, small nucleic acids, and multi-specific antibodies, with substantial growth in contract amounts for these innovative categories [3]. Governance Changes - The company plans to abolish the supervisory board, transferring its responsibilities to the audit committee of the board of directors, in compliance with the new Company Law effective from July 1, 2024 [26][27]. - Amendments to the company's articles of association will reflect this governance change and other necessary updates [28][29].

Group 1 - The core point of the announcement is the resolution of the third extraordinary general meeting of shareholders held by Shanghai Yinos Biotech Co., Ltd., confirming that there were no rejected proposals [1] - The meeting was conducted in compliance with the Company Law and the company's articles of association, with a combination of on-site and online voting methods [2] - All current directors and supervisors attended the meeting, ensuring full representation of the board [3] Group 2 - Two key proposals were approved during the meeting: the reappointment of the accounting firm and the purchase of directors and officers liability insurance [4] - The meeting was held on September 23, 2025, at the designated location in Shanghai [4] - The voting results indicated that all proposals received more than half of the valid voting rights from attending shareholders, with separate counting for minority investors [5] Group 3 - The meeting was witnessed by lawyers from Guohao Law Firm, confirming that the procedures and voting methods adhered to legal requirements [5]

Core Insights - The development of the health and biotechnology industry is emphasized as a strategic emerging industry and a pillar industry for the city, with a focus on high-quality growth and innovation [3][4] - The Jiangxia District is identified as a key area for the health and biotechnology industry, with plans to enhance resource mobilization and collaboration with the Optics Valley Biotech City [3] Group 1: Industry Development - The health and biotechnology industry is highlighted as a significant development direction, with the aim to create an international medical innovation hub in Wuhan [1][3] - The government is committed to promoting technological innovation and industry integration, focusing on key core technology breakthroughs and accelerating the commercialization of scientific achievements [3][4] Group 2: Company Initiatives - Zhongke Kaipu Biotechnology (Hubei) Co., Ltd. is noted for providing comprehensive pharmacological evaluation services, with a call for collaboration with local universities to enhance innovation [1] - Zhuowai (Wuhan) Technology Co., Ltd. has established a high-end medical imaging R&D and production base, focusing on product innovation and clinical application [2] - Wuhan Ruisi Biotechnology Co., Ltd. is recognized for its advancements in epigenomics technology, with encouragement to strengthen market-oriented technology development [2]

Group 1: Industry Development - The health and biotechnology industry is identified as a strategic emerging industry and a pillar industry for the city, with a focus on high-quality development and innovation [3] - Jiangxia District is recognized as a key area for the concentration of health and biotechnology industries, emphasizing the need for responsibility and planning in line with the "14th Five-Year Plan" [3] - The integration of technology innovation and industrial innovation is crucial, with a call for enterprises to take the lead in technological advancements and to focus on market-driven core technology breakthroughs [3] Group 2: Company Initiatives - Zhongke Kaipu Biotechnology (Hubei) Co., Ltd. provides comprehensive pharmacodynamic evaluation services for antiviral drug and vaccine research, aiming to link with local universities for innovation [1] - Zhuowai (Wuhan) Technology Co., Ltd. focuses on the development of minimally invasive surgical imaging equipment, with an emphasis on aligning product development with clinical needs [2] - Wuhan Ruisi Biotechnology Co., Ltd. specializes in advanced epigenomics technology, encouraged to enhance its core competitiveness and expand applications in agriculture and medicine [2] Group 3: Project Development - The Yao Valley Star project aims to create a comprehensive business area within the Guanggu South Health Industry Park, highlighting the importance of high-quality project construction and public service development [1] - There is a strong emphasis on attracting talent, technology, and capital to create a modern park that integrates production, city, and living [1]

Core Viewpoint - The company Jabiou has decided to terminate its acquisition plan for a stake in Ouyi Biotechnology due to changes in the external market environment and after thorough communication with relevant parties [2][3]. Group 1: Acquisition Plan - Jabiou initially planned to acquire 63.21% of Ouyi Biotechnology's shares for approximately 831 million yuan, while also issuing shares to raise matching funds from no more than 35 specific investors [2]. - The acquisition was notable due to an asset appraisal increase of 441.23%, which would have resulted in a goodwill increase of 721 million yuan for Jabiou [2]. - The acquisition plan underwent several adjustments, including a reduction in the stake from 65% to 63.21% and changes in the performance compensation calculation method [2][3]. Group 2: Business Operations - Despite the termination of the acquisition, Jabiou stated that its business operations remain normal and that the decision will not adversely affect daily operations or harm the interests of shareholders, particularly minority shareholders [3]. - The company continues to focus on its strategic goals and aims to enhance its synthetic biology technology system, including omics technology [3]. - In the first half of the year, Jabiou reported a revenue of 307 million yuan, representing a year-on-year growth of 17.6%, and a net profit attributable to shareholders of 108 million yuan, reflecting a 59.01% increase [3].

Core Viewpoint - Zhejiang Tailin Biological Technology Co., Ltd. is implementing an employee stock ownership plan (ESOP) for 2025, which has been reviewed and approved by the legal counsel, Grandall Law Firm (Hangzhou) [2][15]. Group 1: Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. is a legally established and effectively existing joint-stock company with a registered capital of 108.67663 million yuan [4]. - The company is listed on the Shenzhen Stock Exchange's Growth Enterprise Market, with its stock code being 300813, and it was officially listed on January 14, 2020 [5][7]. Group 2: Employee Stock Ownership Plan (ESOP) Details - The ESOP was approved during the fourth board meeting on March 11, 2025, and complies with relevant laws and regulations [8][15]. - The plan allows employees to voluntarily participate, ensuring no forced participation or financial assistance from the company [9][14]. - The stock acquired through the ESOP will have a lock-up period of 12, 24, and 36 months, with specific unlocking ratios of 40%, 30%, and 30% respectively [10]. Group 3: Legal Compliance and Procedures - The legal opinion confirms that the company has fulfilled necessary legal procedures for the ESOP, including obtaining approvals from the board and supervisory committee [12][15]. - The company must still hold a shareholders' meeting to approve the ESOP and disclose the legal opinion two trading days prior to the meeting [15][18]. - The ESOP does not create a concerted action relationship with controlling shareholders or management, ensuring compliance with relevant regulations [17]. Group 4: Information Disclosure - The company has disclosed the ESOP draft, management measures, and relevant resolutions through designated media [17][18]. - Ongoing information disclosure obligations will continue as the ESOP progresses, in accordance with regulatory requirements [18].